INHSU 2023 Abstract Submissions
Late breaker deadline
Late breaker abstracts open Monday 1 May and the deadline is: 11:59PM (CEST) Sunday 28 May 2023.
There will be no extensions.
Download the below guidelines and template and submit via our online portal.
First time writing an abstract? Contact email@example.com to be connected to one of our members who can assist you.
INHSU 2023 welcomes submissions of abstracts for original contribution to the field in the following scientific themes, with the objective of enhancing global health and quality of life of people who use drugs. Abstracts that focus on health issues among people who use drugs beyond hepatitis C are welcomed and encouraged.
The International Network on Health and Hepatitis in Substance Users has previously published research priorities focused on hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Consistent with these priorities, INHSU 2023 is specifically, but not exclusively, looking to accept abstracts on the following topics:
- Epidemiology of injecting drug use, HCV, and HIV among people who use or inject drugs
- Epidemiology of harms associated with drug use (e.g. overdose, injecting-related infections)
- Prevention of HCV and HIV infection among people who use or inject drugs
- Prevention of drug-related harms among people who use or inject drugs
- HCV testing among people who use or inject drugs
- Linkage to HCV care and treatment among people who use or inject drugs
- DAA HCV treatment among people who use or inject drugs
- Reinfection following successful treatment among people who use or inject drugs
- Empirical or real-world evidence documenting HCV elimination efforts
- Integration of services to address HCV and other infectious diseases (e.g. HIV)
- Interventions to enhance health care for people who inject drugs
- Public health policy and service delivery planning
We encourage submissions that highlight specific characteristics or sub-populations (e.g. gender, age) for which specific interventions should be developed to ensure equal access to services. We also encourage submissions from low and middle-income country settings to inform epidemiology and delivery of interventions to enhance care among people who use or inject drugs.